[en] X-linked Alport syndrome (AS) is a heritable disorder which is associated with mutations in the type IV collagen alpha 5 (IV) chain gene (COL4A5) located on chromosome X. Following renal transplantation, an average of 6% of male AS patients develop anti-GBM nephritis. We studied the specificity of the antibodies against type IV collagen in the serum of a patient with COL4A5 partial deletion. The specificity of these alloantibodies was determined against collagenase-digested GBM, as well as against recombinant non-collagenous (NC1) domains of the type IV collagen alpha 1(IV)-alpha 6(IV) chains expressed in escherichia coli. Immunoblotting and ELISA demonstrated that these antibodies bound specifically to the NC1 domain of alpha 5(IV) collagen. There was no binding to the NC1 domain of the other chains, including the Goodpasture antigen. Competitive ELISA confirmed the results obtained by ELISA and immunoblotting. This patient developed alloantibodies directed against antigens present in the grafted kidney, but absent from his Alport kidney. The pathogenesis of post-transplantation glomerulonephritis in the Alport patient studied is thus similar to that of Goodpasture syndrome, with the exception that the pathogenic antibodies are targeted to another alpha chain of type IV collagen.
Disciplines :
Urology & nephrology
Author, co-author :
Dehan, Pierre ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Van den Heuvel, L. P.
Smeets, H. J.
Tryggvason, K.
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Language :
English
Title :
Identification of Post-Transplant Anti-Alpha 5 (Iv) Collagen Alloantibodies in X-Linked Alport Syndrome
Yoshikawa N, Cameron AH, White RH. The glomerular basal lamina in hereditary nephritis. J Pathol 1981; 135: 199-205
Hudson BG, Reeders ST, Tryggvason K. Type IV collagen: structure, gene organization, and role in human diseases. J Biol Chem 1993; 268: 26033-26036
Barker DF, Hostikka SL, Zhou J et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990; 248: 1224-1227
Kleppel MM, Fan WW, Cheong HI, Michael AF. Evidence for separate networks of classical and novel basement membrane collagen. J Biol Chem 1992; 267: 4137-4142
Ninomiya Y, Kagawa M, Iyama K et al. Differential expression of two basement membrane collagen genes, COL4A6 and COL4A5, demonstrated by immunofluorescence staining using peptide-specific monoclonal antibodies. J Cell Biol 1995; 130: 1219-1229
Kleppel MM, Kashtan C, Santi PA, Wieslander J, Michael AF. Distribution of familial nephritis antigen in normal tissue and renal basement membrane of patients with homozygous and heterozygous Alport familial nephritis. Lab Invest 1989; 61: 278-289
Kashtan C, Kim Y. Distribution of the α1 and α2 chains of collagen IV and of collagens V and VI in Alport syndrome. Kidney Int 1992; 42: 115-126
Kashtan C, Michael AF. Alport syndrome: from bedside to genome to bedside. Am J Kidney Dis 1993; 22: 627-640
Shah B, First MR, Mendoza NC, Clyne DH, Alexander JW, Weiss MA. Alport's syndrome: risk of glomerulonephritis induced by anti-glomerular-basement-membrane antibody after renal transplantation. Nephron 1988; 50: 34-38
Pirson Y, Lannoy N, Smaers M, Tryggvason K, Verellen-Dumoulin C. Deletion in the COL4A5 gene and outcome of renal transplantation in Alport syndrome. Nephrol Dial Transplant 1992; 7: 785a
Hudson BG, Kalluri R, Gunwar S et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the a3 (IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int 1992; 42: 179-187
Kalluri R, Weber M, Netzer K-O, Sun MJ, Neilson EG, Hudson BG. COL4A5 gene deletion and production of post-transplant anti-a3(IV) collagen alloantibodies in Alport syndrome. Kidney Int 1994; 45: 721-726
Kleppel MM, Fan WW, Cheong HI, Kashtan CE, Michael AF. Immunochemical studies of Alport antigen. Kidney Int 1992; 41: 1629-1637
Ding J, Kashtan CE, Fan WW et al. A monoclonal antibody marker for Alport syndrome identifies the Alport antigen as the α5 chain of type IV collagen. Kidney Int 1994; 46: 1504-1506
Mochizuki T, Lemmink HH, Mariyama M et al. Identification of mutations in the α3 and α4 type IV collagen genes in autosomal recessive Alport syndrome. Nature Genet 1994; 8: 77-82
Kalluri R, van den Heuvel LP, Smeets HJM et al. A COL4A3 gene mutation and post-transplant anti-α3(IV) collagen alloantibodies in Alport syndrome. Kidney Int 1995; 47: 1199-1204
Smeets HJM, Melenhorst JJ, Lemmink HH et al. Different mutations in the COL4A5 collagen gene in two patients with different features of Alport syndrome. Kidney Int 1992; 42: 83-88
van den Heuvel LPWJ, Schroder CH, Savage COS et al. The development of anti-glomerular basement membrane nephritis in two children with Alport's syndrome after renal transplantation: characterization of the antibody target. Pediatr Nephrol 1989; 3: 406-413
Soininen R, Haka-Risku T, Prockop DJ, Tryggvason K. Complete primary structure of the α1 chain of human basement membrane (type IV) collagen. FEBS Lett 1987; 225: 188-194
Hostikka SL, Tryggvason K. The complete primary structure of the α2 chain of human type IV collagen and comparison with the α1(IV) chain. J Biol Chem 1988; 263: 19488-19493
Mariyama M, Leinonen A, Mochizuki T, Tryggvason K, Reeders S. Complete primary structure of the human α3(IV) collagen chain: coexpression of the α3(IV) and α4(IV) collagen chains in human tissues. J Biol Chem 1994; 269: 23013-23017
Leinonen A, Mariyama M, Mochizuki T, Tryggvason K, Reeders S. Complete primary structure of the human type IV collagen a4(IV) chain: comparison with structure and expression of the other a(IV) chains. J Biol Chem 1994; 269: 26172-26177
Zhou J, Hertz JM, Leinonen A, Tryggvason K. Complete amino acid sequence of the human α5(IV) collagen chain and identification of a single base mutation in exon 23. J Biol Chem 1992; 267: 12475-12481
Oohashi T, Sugimoto M, Mattei MG, Ninomiya Y. Identification of a new collagen IV chain, α6(IV), by cDNA isolation and assignment of the gene to chromosome Xq22, which is the same locus for COL4A5. J Biol Chem 1994; 269: 7520-7526
Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli in fusion with Glutathione S-transferase. Gene 1988; 67: 31-40
van den Heuvel LPW, Savage COS, Wong M et al. The glomerular basement membrane defect in Alport-type hereditary nephritis: absence of cationic antigenic components. Nephrol Dial Transplant 1989; 4: 770-775
Rennard SI, Berg R, Martin GR, Foidart JM, Gehron Robey P. Enzyme-linked immunoassay (ELISA) for connective tissue component. Anal Biochem 1980; 104: 205-214
Kalluri R, Gattone VH, Noelken ME, Hudson BG. The α3 chain of type IV collagen induces autoimmune Goodpasture syndrome. Proc Natl Acad Sci USA 1994; 91: 6201-6205
Weber M, Meyer zum Büschenfelde K-H, Köhler H. Immunological properties of the human Goodpasture target antigen. Clin Exp Immunol 1988; 74: 289-294
Kashtan C, Fish AJ, Kleppel M, Yoshioka K, Michael AF. Nephritogenic antigen determinants in epidermal and renal basement membrane of kindreds with Alport-type familial nephritis. J Clin Invest 1986; 78: 1035-1044
Kashtan CE, Butkowski RJ, Kleppel MM, First MR, Michael AF. Post transplant anti-glomerular basement membrane nephritis in related males with Alport syndrome. J Lab Med 1990; 116: 508-515
Antignac C, Dechenes G, Gros F, Knebelman B, Tryggvason K, Gubler M-C. Mutations in COL4A5 gene in Alport syndrome. J Am Soc Nephrol 1991; 2: 249a
Peten E, Pirson Y, Cosyns J-P, Squifflet G et al. Outcome of thirty patients with Alport's syndrome after renal transplantation. Transplantation 1991; 52: 823-826
Rassoul Z, Al-Khader AA, Al-Sulaiman M, Dhar JM, Coode P. Recurrent allograft antiglomerular basement membrane glomerulonephritis in a patient with Alport's syndrome. Am J Nephrol 1990; 10: 73-76
Heikkilä P, Parpala T, Lukkarinen O, Weber M, Tryggvason K. Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system - first steps towards gene therapy of Alport syndrome. Gene Ther 1996; 3: 21-27
